carboplatin,etoposide,atezolizumab,tiragolumab
roche
['skyscraper-02', 'atezo', 'tiragolumab', 'sclc']
skyscraper-02 study: addition of tigit inhibitor tiragolumab to atezolizumab and chemotherapy did not provide further benefit over atezolizumab + chemotherapy in patients with untreated es-sclc no difference in pfs or os
#asco22 
Radiation Oncologist and Clinical Director, wouldbe cyclist, sometimes pianist. Views are my own, RTs not